{"name":"Myrtelle Inc.","slug":"myrtelle-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxPb0ktazBtTkJ3QWxybGtFTFFJb1N1aUhXX3BUbTFCQkpyd1pMSTdlZmhEUktWSldLRmhJV2t5SE84Zk9Za1F0THotODkxcHd5UkJYLV9nVXZHZ05Jd0lWVktBM284QWRnMHZyRy1ZY3NWMXpRUXp2TmhpME53SUhzTGgxTzMweHRRUnBzR2Y4QUVzUkxyWlpCY2E5b1F5bEVVdXhSanhBZW9Fbm5hT1pSSEF3aDhIUll2bXQwUS1FT18tMnNVS1d1TzlFSFl2OHVJcVFfdXlfdVkxU0U4YTFScVlMZjRlSTZKV0dRSDdB?oc=5","date":"2026-03-30","type":"trial","source":"Barchart.com","summary":"Hearing Loss Clinical Trial Pipeline Shows Potential with Active Contributions from 30+ Key Companies | DelveInsight - Barchart.com","headline":"Hearing Loss Clinical Trial Pipeline Shows Potential with Active Contributions from 30+ Key Companies | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxOR0dXN0FNeGhOTkdSZi1OLVgxTHIwTmVrOWF4ZER5LVpwZ3NpekxwVUZGbERnLV92NTFTdGszWEFjN0dUNmp3dWk4UW9wYjZuLVQ1d2FoYkVyS3llX09Dc0pmRWFrQTB1N3hWN081VU5zU2tHUGFIS0RBakpWRkFqLUJiQUJISmtyWGZRQlVES296QmFsNE45TWktNzFvRWtncDk1ckJBWko2c3V5dDJrd2tVN1l1cUI3NTNoQ2hBZjh1SWxUanRmVk1BUlhjZw?oc=5","date":"2025-10-13","type":"pipeline","source":"CGTLive®","summary":"Myrtelle’s Canavan Disease Gene Therapy Effects Significant Decrease in CSF NAA and Increases in Brain Myelin Volume - CGTLive®","headline":"Myrtelle’s Canavan Disease Gene Therapy Effects Significant Decrease in CSF NAA and Increases in Brain Myelin Volume - C","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwJBVV95cUxQTTNmSUJ2am01RjFaek51eEw2ak04eUVNeVQ2ZXI4MDNUUXNBam05TXhaRGZoU3YzWFNDZHk3Z2wwUVBncDFDbi0wWmJONm51dE5nTTBfNzJ1ZWRoc0lZVFlvRm5jd1VveG5fMHRYSDlSdkdBM2NGREhXR185WVhzSW9EMExBTGQ2ZVppRkt3eE8wUWdVNGoySzdiWUJHUHpka1pTMmZvSVdHOGJEcGpSbkhzQVluajVKTHNULVFuOGY0ZExuRkM3aDlLSkFHNTZJeHBqUldPWEdPRzdjcXo3Ulg5UHJiMXI0ajdYcjFaQ3JONk0yR2kxZkpJN2NwU1NOQl9vUU41cjNWSnpYOXF4dTZUSVRsRnpDLW9nMXJac0tER1gtaVBpRVNMRGRaX3M0aVRIS1JnUk4tMmdEakxJ?oc=5","date":"2025-10-06","type":"trial","source":"PR Newswire","summary":"Myrtelle Announces Presentation of Encouraging Interim Results from its Phase 1/2 Gene Therapy Trial for Canavan Disease at the 2025 Cell & Gene Meeting on the Mesa - PR Newswire","headline":"Myrtelle Announces Presentation of Encouraging Interim Results from its Phase 1/2 Gene Therapy Trial for Canavan Disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxPNkNzNVU0SGpHZ182b3d4emlpbDlIUG5aSTRkSHppZnQ1b2JPOGxSUkNMcGRSTjVCWVFxZG9YSTdQVGpwaFdibW41T3BTbjNJM1ZaYzN3Q1JnT3lOUzZhUjd1ZXVfVW01ZlFUZmZvWHU0c2xmNzVFWGhpMWFnUmZldnE2TWZzS0k2Ty1pRmJ1ZUNNQzZWOVpBelJUaHRQcjdiVXBDMGdfR2VuWTZuMzJuNDJTSlpYa2M?oc=5","date":"2025-07-11","type":"pipeline","source":"BioProcess International","summary":"Myrtelle launches commercial manufacturing for Canavan gene therapy - BioProcess International","headline":"Myrtelle launches commercial manufacturing for Canavan gene therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAJBVV95cUxNdWdza214QlhicjItZEdEUnFUNE9oUnFzd2xtTlBXeWZqYWNfc2dBemM2bzdsWkpzZzhLTllZWVRqdjdXd2p2Xy1wSkpxTXlvWFl5d1VrSTdxMFpMNXB5VVZzUnp4bjVOcUdyeTQ1TFo2OWRHY2hvV2ZISmFXX0x4OVY5ZXp1V1NlOUFPR0x2UVFIa1ZFT2xCVUM0MkRjSE1vd0R3cTR0MXVpOEhKaXMxX1N4S2hOLTd5TW15MEtFc1A5LUtYaUpKcnBkcGptMW5TUE5uTUlzY2M3aG16eHhmZlV0d05FRjRSdWRsTzExc1dFcGx3dllMVVpCd2RvWVpvcUtqeTgtUHpveHJjQjRmSk9qYTgwQVZvdnpRaA?oc=5","date":"2025-07-08","type":"pipeline","source":"PR Newswire","summary":"Myrtelle Launches Manufacturing of First-in-Class Gene Therapy for Canavan Disease in Strategic Alliance with Charles River and Viralgen - PR Newswire","headline":"Myrtelle Launches Manufacturing of First-in-Class Gene Therapy for Canavan Disease in Strategic Alliance with Charles Ri","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxNSXZWNERmUkREUE9yYVFzMGJhZ2tqcEM2dmZtZUx6THpZejN1dExuVzMyMExQMUVYT1NDcEZxWFhuTFZSaVZCWFk5ZllSdm1Hei1QWHUxbkF5WEJEMVFTWTZOc0pQZUd0YVpDUjZJaHhUV2tVZWpTODRwaVRzQnZ5RU90dHB5eGl3TTg5cUdPSXZzRkszOWl0MTFyNFc1RE1WN0xVT045aWloNWRUTVQxVHZyQnRndmJJbThLamZkY01mczVPQmE2clMyd0QtZjFDSFVjQQ?oc=5","date":"2024-10-30","type":"pipeline","source":"CGTLive®","summary":"BridgeBio Pharma’s Gene Therapy BBP-812 Effects Progressive Improvement in Motor Function in Patients With Canavan Disease - CGTLive®","headline":"BridgeBio Pharma’s Gene Therapy BBP-812 Effects Progressive Improvement in Motor Function in Patients With Canavan Disea","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxQNzlWWjE3OUJoaDFsb3BQMzl6SkxKcEg2Y3c5Z0l5R1g0Z3BPUzhDOHlGbjZtMk5VdFlQWkVPNEluY1poWk5pRWtxYnpBSWVmTHhuQ2dLTC12UE1TYTVOaUt3dUEzSTloT1Q5QnY5ai1zaFNHY0s3VXlfUWYtV2p6OE5nM1BUeVlYZVVPbHY3N0syQ0wybkVJTzNkamZuMkJvdVIwZVRQTG1Ld2hfcnBWUnpoeHdfc3BzY2lMUzZwV2ZVVFZmUDdVdERERQ?oc=5","date":"2024-10-02","type":"trial","source":"CGTLive®","summary":"Myrtelle’s Canavan Disease Gene Therapy rAAV-Olig001-ASPA Decreases N-Acetylaspartate Levels in Phase 1/2 Study - CGTLive®","headline":"Myrtelle’s Canavan Disease Gene Therapy rAAV-Olig001-ASPA Decreases N-Acetylaspartate Levels in Phase 1/2 Study - CGTLiv","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxQbE1VTWViT0hGTzJBMUhQaWE3RzZhaHVsdXdickZYOThxdVF6dmZOdWNKd0gtYW5URFBjbGNaQmYxd2p1cXdPQUhXVFJ1RXVCaTBia0JCQ2daZ1JkbnU5VHR0MHd4NHFRN3poSUhpY0pVcWZBWUVhZmdDN3J5VU4wZ2ZnRkt5UFVRWGk5aDFFeFNDaTJOd2F3T2FBRmFIenRMaXZRNHlKU3p0LWl2cGlDUHQ1WWloU1RwWFdZZEpyNjE1LVJuaHFEOWJOSXRwU21mSUpYOWxYOFVQOTFWajAtNVNmNFJCZXNsM2c?oc=5","date":"2022-10-03","type":"deal","source":"Business Wire","summary":"Myrtelle and Forge Biologics Announce Viral Vector and Plasmid DNA cGMP Manufacturing Partnership - Business Wire","headline":"Myrtelle and Forge Biologics Announce Viral Vector and Plasmid DNA cGMP Manufacturing Partnership","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}